Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 615

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1B
Chunk 615
---
  Amount  capital  deficit  (losses)/gain  equity                    Balance as of January 1, 2024   17,667,663  $17,191,315  $(5,011,891 ) $(1,844,278 ) $(677,294 ) $9,657,852                          Issuance of shares@  300,000   141,000   -   -   -   141,000                          Net loss for the year  -   -   -   (1,598,342)  -   (1,598,342)                         Foreign currency translation gain  -   -   -   -   122,294   122,294                          Balance as of December 31, 2024  17,967,663  $17,332,315  $(5,011,891 ) $(3,442,620) $(555,000) $8,322,804 

@ 300,000 shares of common stock were issued for professional services rendered

See accompanying notes to the consolidated financial statements.

 F-7Table of Contents

BIONEXUS GENE LAB CORP.CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023(Currency expressed in United States Dollars (“US$”))(Audited)  Year Ended   December 31,   2024  2023 Cash flows from operating activities:      Net loss $(1,598,342) $(2,629,043)         Adjustments to reconcile net loss to net cash used in operating activities:        Amortization of right-of-use asset  48,983   25,170 Allowances for expected credit losses  883,533   942,800 Recoveries for expected credit losses  (1,689,412)  - Bad debts written off  6,344   6,261 Depreciation of property, plant and equipment  104,160   83,253 Dividend income  (68,130)  (61,409)Fair value gain on investments in equity